Approval Probability
TA Base Rate
Adjusted LOA
ML Risk
Also known as Notch inhibitor, BMS-906024 (Notch inhibitor)
BMS-906024 · 3 trials · 3 indications
| Arm | Type | Description |
|---|---|---|
| Arm A: Paclitaxel + BMS-906024 | EXPERIMENTAL | Paclitaxel 80 mg/m2 solution and BMS-906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity |
| Arm B: FOLFIRI (5FU, Leucovorin, Irinotecan) + BMS-906024 | EXPERIMENTAL | 5FU Bolus 400 mg/m2, 5FU Infusion 2400 mg/m2, Irinotecan 180 mg/m2 solution, Leucovorin 400 mg/m2 solution intravenously once every 2 weeks and BMS- 906024 4 mg or 6 mg solution intravenously once weekly continuously until disease progression or unacceptable toxicity |
| Arm C: Carboplatin/Paclitaxel + BMS-906024 | EXPERIMENTAL | Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once weekly intravenously continuously until disease progression or unacceptable toxicity |
| Arm D: Paclitaxel + BMS-906024 | EXPERIMENTAL | Paclitaxel 80 mg/m2 solution once weekly and BMS-906024 4 mg or 6 mg solution once every 2 weeks intravenously continuously until disease progression or unacceptable toxicity |
| Arm F: Carboplatin/Paclitaxcel and BMS-906024 | EXPERIMENTAL | Carboplatin AUC 6 / Paclitaxel 200 mg/m2 solution once every 3 weeks and BMS-906024 4 mg or 6 mg solution once every 3 weeks intravenously continuously until disease progression or unacceptable toxicity |
| Escalation Phase: BMS-906024 | EXPERIMENTAL | BMS-906024 escalating doses starting at 0.3 mg solution for intravenous (IV) administration once weekly continuously until disease progression or unacceptable toxicity |
| Expansion Phase: BMS-906024 + Dexamethasone | EXPERIMENTAL | BMS-906024 maximum tolerated dose (To be determined) solution for IV administration once weekly and Dexamethasone 20mg/day tablet by mouth (Oral) for 3-4 days every week for 3-4 weeks per cycle continuously until disease progression or unacceptable toxicity |
| Arm A1 (Escalation): BMS-906024 | EXPERIMENTAL | BMS-906024 solution intravenously as specified |
| Arm A2 (Expansion): BMS-906024 | EXPERIMENTAL | BMS-906024 solution intravenously as specified |
| Arm B1 (Escalation): BMS-906024 | EXPERIMENTAL | BMS-906024 solution intravenously as specified |
| Arm B2 (Expansion): BMS-906024 | EXPERIMENTAL | BMS-906024 solution intravenously as specified |
| Name | Type | Description |
|---|---|---|
| Paclitaxel | DRUG | - |
| 5-Fluorouracil (5FU) | DRUG | - |
| Carboplatin | DRUG | - |
| Leucovorin | DRUG | - |
| Irinotecan | DRUG | - |
| BMS-906024 | DRUG | - |
| Dexamethasone | DRUG | - |
For more information regarding BMS clinical trial participation, please visit www.BMSStudyConnect.com. Inclusion Criteria: * Subjects with advanced or metastatic solid tumors for whom a chemotherapy regimen is considered appropriate * Subjects with non-small cell lung cancer and triple-negative br...
Top 2 of 4 competitors
| Company | Ticker | Trials | Lead Phase | Drugs |
|---|---|---|---|---|
| GE Healthcare Technologies Inc. | GEHC | 1 | PHASE1 | GEH200520/GEH200521 |
| Ascentage Pharma Group International Unsponsored ADR | AAPG | 1 | PHASE1 | Olverembatinib |
BMS-906024 is an investigational small molecule developed by Bristol-Myers Squibb for the treatment of cancer. It has been studied in advanced or metastatic solid tumors and in acute T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma. It remains in clinical development and is not an approved therapy.
BMS-906024 has been studied in adults with advanced or metastatic solid tumors and in adults with acute T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma. Trials evaluated it both as a single agent and in combination with chemotherapy regimens including weekly paclitaxel, 5FU plus irinotecan, and carboplatin plus paclitaxel.
Bristol-Myers Squibb Company, which trades on the New York Stock Exchange under the ticker BMY, is the developer of BMS-906024. The company sponsored the clinical trials evaluating the compound in solid tumors and in T-cell lymphoblastic leukemia and lymphoma.
BMS-906024 is in Phase 1 clinical development. Both of its listed Phase 1 trials have been completed, and no trials are currently active. It is an investigational agent and has not been approved by the FDA for any indication.
BMS-906024 was evaluated in Phase 1 trials NCT01653470, which tested it with chemotherapy in advanced or metastatic solid tumors, NCT01363817, which studied weekly intravenous doses in acute T-cell lymphoblastic leukemia or T-cell lymphoblastic lymphoma, and NCT01292655, which studied intravenous doses in advanced or metastatic solid tumors.
Across its completed Phase 1 studies, BMS-906024 enrolled a total of 235 participants. NCT01653470 enrolled 141 patients, NCT01292655 enrolled 94 patients, and NCT01363817 enrolled 31 patients. All trials enrolled adults aged 18 years and older and were conducted at sites in the United States, Canada, and Europe.